ERBB2 and neoplasm: Again, the HER2-CD3-Fc bsAb efficiently bound to the 4T1-HER2-ECD-IV cells (Figure 5G) and induced robust T cell cytotoxicity (Figure 5J) and IFN-λ/granzyme B secretion (Figure 5M,P) against the subdomain-IV-expressing tumor cells.